Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04170283 · ClinicalTrials.gov registry record · Phase 3
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
A Phase 3 study of B-cell Malignancies, sponsored by BeiGene.
- Active
- Registry status
- Phase 3
- Development phase
- 955
- Enrollment target
- 20
- Study locations
NCT04170283 is a Phase 3 study of B-cell Malignancies that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 955 participants, above the 175-participant average among 6 other B-cell Malignancies trials with a reported enrollment target (446% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT04170283, a Phase 3 study of B-cell Malignancies, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 955 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Tislelizumab
Study Locations (20)
Colorado
- Rocky Mountain Cancer Centers Centennial - Centennial
- Colorado Blood Cancer Institute - Denver
Florida
- Florida Cancer Specialists Fort Myers - Fort Myers
- Scri Florida Cancer Specialists North - St. Petersburg
New Jersey
- Summit Medical Group - Florham Park
- Atlantic Health System - Morristown
Oregon
- Oncology Associates of Oregon Willamette Valley Cancer Center - Eugene
- Oregon Health and Science University - Portland
Tennessee
- Scri Tennessee Oncology Chattanooga - Chattanooga
- Tennessee Oncology - Nashville
Arizona
- Banner Md Anderson Cancer Center - Gilbert
Arkansas
- Carti Cancer Center - Little Rock
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 955 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04170283
The ClinicalTrials.gov registry entry for NCT04170283 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 955 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 175-participant average among 6 other B-cell Malignancies trials with a reported enrollment target (446% higher). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with B-cell Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.
NCT04170283 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Colorado, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04170283 about?
NCT04170283 is a clinical study titled "Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies". The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
What is the current status of trial NCT04170283?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 955 participants. The study started on 2020-01-16. Estimated completion is 2028-12.
What conditions does trial NCT04170283 study?
This clinical trial studies the following conditions: B-cell Malignancies.
What interventions are being tested in trial NCT04170283?
The interventions under investigation include: Zanubrutinib (DRUG), Tislelizumab (DRUG).
Who is sponsoring clinical trial NCT04170283?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04170283 being conducted?
This trial has 20 study locations across Arizona, Arkansas, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RECRUITING · Phase 1
-
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RECRUITING · Phase 2
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.